MAZE Stock: Price, Earnings History and SEC Filings
Maze Therapeutics, Inc. (MAZE) last traded at $31.48, down 1.41% on the latest session and up 15.8% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.76 against an analyst estimate of $-0.76, a beat of 0.0%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
MAZE earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 11, 2026 | $-0.76 | $-0.76 | +0.00% |
| Mar 2026 | May 12, 2026 | $-0.45 | $-0.43 | -4.65% |
| Dec 2025 | Mar 25, 2026 | $-0.65 | $-0.73 | +10.96% |
| Sep 2025 | Nov 6, 2025 | $-0.66 | $-0.74 | +10.81% |
MAZE beat the analyst EPS estimate in 2 of its last 4 reported quarters. Source: Nasdaq.
How MAZE reacts to earnings
Across its last 7 earnings releases, MAZE moved 7.3% on average the next session, in either direction. It rose after 3 of 7 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-11 | After close | +0.81% |
| 2026-05-12 | After close | +4.58% |
| 2026-03-25 | Before open | -35.24% |
| 2025-11-06 | After close | -3.48% |
| 2025-08-12 | After close | -1.02% |
| 2025-05-14 | After close | +2.10% |
| 2025-03-31 | Before open | -3.59% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
Latest SEC filings for MAZE
- 8-K · Oct 16, 2026Material agreement, Unregistered share sale, Financial statements and exhibits
- 8-K · Aug 17, 2026Officer or director change, Regulation FD disclosure, Financial statements and exhibits
- 10-Q · Aug 11, 2026
- 8-K · Aug 11, 2026Results of operations, Financial statements and exhibits
- 8-K · Jun 10, 2026Shareholder vote
- 8-K · May 22, 2026Officer or director change
- 10-Q · May 12, 2026
- 8-K · May 12, 2026Results of operations, Financial statements and exhibits
- DEF 14A · Apr 28, 2026
- 8-K · Apr 22, 2026Other events, Financial statements and exhibits
Insider filing activity
MAZE insiders filed 18 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
MAZE news
- What Makes Maze Therapeutics, Inc. (MAZE) a New Buy StockOct 19, 2026 · finance.yahoo.com
- Intel upgraded, PayPal downgraded: Wall Street's top analyst callsOct 19, 2026 · finance.yahoo.com
- How Much Upside is Left in Maze Therapeutics, Inc. (MAZE)? Wall Street Analysts Think 123.39%Oct 19, 2026 · finance.yahoo.com
About Maze Therapeutics, Inc.
Maze Therapeutics, Inc. (MAZE) is a US-listed public company on Nasdaq. The SEC classifies its business as Biological Products (no Diagnostic Substances). It is incorporated in DE. Its fiscal year ends in December.